Drug

D1014 | niflumic acid

Molecular Formula C13H9F3N2O2
Molecular Weight 282.22
Structure
State solid
Protein binding 90% bound to plasma proteins.
Half life 2.5 hours
Absorption Well absorbed following oral administration.

M

M02AA17 Niflumic acid


[M02AA] Antiinflammatory preparations, non-steroids for topical use


[M02A] TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN


[M02] TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN


[M] Musculoskeletal system


M01AX02 Niflumic acid


[M01AX] Other antiinflammatory and antirheumatic agents, non-steroids


[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS


[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS


[M] Musculoskeletal system


Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 13.02±2.17 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 15.45 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 6.71±1.14 rat hepatocytes MMP assay decrease IC50 163

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 45 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (93.33%): Harmful if swallowed [Warning Acute toxicity, oral]


H312 (93.33%): Harmful in contact with skin [Warning Acute toxicity, dermal]


H315 (95.56%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (95.56%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H332 (93.33%): Harmful if inhaled [Warning Acute toxicity, inhalation]


H335 (93.33%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 oral 350mg/kg (350mg/kg) United States Patent Document. Vol. #4122202,
rat LD50 intraperitoneal 100mg/kg (100mg/kg) United States Patent Document. Vol. #3466373,
guinea pig LD50 intravenous 174mg/kg (174mg/kg) United States Patent Document. Vol. #3466373,
mouse LD50 intravenous 152mg/kg (152mg/kg) Therapie. Vol. 22, Pg. 157, 1967.
mouse LD50 intraperitoneal 196mg/kg (196mg/kg) Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 68, Pg. 683, 1972.
rat LD50 oral 250mg/kg (250mg/kg) behavioral: analgesia Journal of Medicinal Chemistry. Vol. 16, Pg. 780, 1973.


  • 1td7 2(3'-trifluormethylanilino)-nicotinic acid 2-((3-(Trifluoromethyl)phenyl)amino)nicotinic acid
    2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid 2-(3-(Trifluoromethyl)anilino)nicotinic acid 2-(3-(Trifluoromethyl)phenylamino)nicotinic acid
    2-(3-Trifluoromethyl-phenylamino)-nicotinic acid 2-(3-Trifluoromethylanilino)nicotinic Acid 2-(3-[Trifluoromethyl]anilino)nicotinic acid
    2-(3-trifluoromethylphenoxy)nicotinamide 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid 2-(|A,|A,|A-Trifluoro-m-toluidino)nicotinic acid;
    2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid
    2-[3-(Trifluoromethyl)anilino]-3-pyridinecarboxylic acid 2-[3-(Trifluoromethyl)anilino]nicotinic acid 2-[3-(Trifluoromethyl)anilino]nicotinic acid
    2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid 2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID
    2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid 3-Pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)- 3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-
    394N007 4394-00-7 4U5MP5IUD8
    5-22-13-00598 (Beilstein Handbook Reference) AB00052255 AB00052255-17
    AB00052255_18 AB00052255_19 AB0012229
    AB1004097 AC-2652 ACMC-209jvx
    AK-72979 AKOS000519590 AM20070143
    ANW-30043 Acide niflumique Acide niflumique [French]
    Acide niflumique [INN-French] Acido niflumico Acido niflumico [INN-Spanish]
    Acido niflumico [Italian] Acidum niflumicum Acidum niflumicum [INN-Latin]
    Actol Actol, analgesic Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino
    Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French] BBL003619 BDBM85507
    BPBio1_000078 BR-72979 BRD-K98763141-001-04-3
    BRD-K98763141-001-06-8 BRD-K98763141-001-17-5 BRN 0489360
    BSPBio_000070 BSPBio_001393 BSPBio_003069
    Bio1_000114 Bio1_000603 Bio1_001092
    Bio2_000113 Bio2_000593 C13698
    CAS-4394-00-7 CAS_4394-00-7 CBiol_001828
    CCG-40157 CCRIS 5740 CHEBI:34888
    CHEMBL63323 CS-2614 CTK4I7886
    D08275 DB04552 DL-457
    DSSTox_CID_3368 DSSTox_GSID_23368 DSSTox_RID_76996
    DTXSID1023368 DivK1c_000277 Donalgin
    EINECS 224-516-2 EU-0100845 FT-0603659
    Forenol GS-3202 GTPL2439
    HMS1361F15 HMS1568D12 HMS1791F15
    HMS1921D12 HMS1989F15 HMS2090D19
    HMS2095D12 HMS2234F11 HMS3262J11
    HMS3374H01 HMS3402F15 HMS3649A08
    HMS3656P14 HMS3712D12 HMS500N19
    HY-B0493 IDI1_000277 IDI1_033863
    JZFPYUNJRRFVQU-UHFFFAOYSA-N KBio1_000277 KBio2_000113
    KBio2_001833 KBio2_002681 KBio2_004401
    KBio2_005249 KBio2_006969 KBio3_000225
    KBio3_000226 KBio3_002569 KBioGR_000113
    KBioGR_000505 KBioSS_000113 KBioSS_001833
    KS-00000CB5 KSC587Q8N LP00845
    LS-96639 Landruma Lopac-N-0630
    Lopac0_000845 MCULE-3027710274 MFCD00010569
    MLS000069713 MLS001076327 N 0630
    NCGC00015724-01 NCGC00015724-02 NCGC00015724-03
    NCGC00015724-04 NCGC00015724-05 NCGC00015724-06
    NCGC00015724-07 NCGC00015724-08 NCGC00015724-09
    NCGC00015724-10 NCGC00015724-11 NCGC00015724-12
    NCGC00015724-13 NCGC00015724-14 NCGC00015724-17
    NCGC00023636-03 NCGC00023636-04 NCGC00023636-05
    NCGC00023636-06 NCGC00023636-07 NCGC00023636-08
    NCGC00023636-09 NCGC00261530-01 NFL
    NINDS_000277 NSC-758196 NSC758196
    NSC_4488 Nicotinic acid, 2-(.alpha.,.alpha.,.alpha.-trifluoro-m-toluidino)- Nicotinic acid, 2-(alpha,alpha,alpha-trifluoro-m-toluidino)-
    Niflamol Niflugel (TN) Niflumate
    Niflumic acid (Hit 16) Niflumic acid (INN) Niflumic acid [INN:BAN:DCF]
    Niflumic acid [INN:DCF] Niflumic acid, European Pharmacopoeia (EP) Reference Standard NiflumicAcid
    Nifluminic acid Nifluril Opera_ID_1746
    Pharmakon1600-01502015 Prestwick0_000255 Prestwick1_000255
    Prestwick2_000255 Prestwick3_000255 Prestwick_890
    PubChem21796 Q304285 RTR-017015
    S00109 SBB001146 SBI-0050821.P003
    SC 1332 SCHEMBL24706 SMR000058199
    SPBio_000928 SPBio_002289 SPECTRUM1502015
    SR-01000000231 SR-01000000231-11 SR-01000000231-2
    SR-01000000231-5 SR-01000000231-6 ST013871
    ST24027408 STK803109 SW197011-3
    Spectrum2_000794 Spectrum3_001485 Spectrum4_000043
    Spectrum5_001216 Spectrum_001353 T7852
    Tox21_110206 Tox21_110206_1 Tox21_500845
    UNII-4U5MP5IUD8 UP 83 UP-83
    W-106215 ZINC125031 ni-flumic acid
    niflumic acid niflumic-acid s3018

    DrugBank Name niflumic acid
    DrugBank DB04552
    CAS Number 439081-18-2, 4394-00-7, 910332-88-6
    PubChem Compound 4488
    KEGG Compound ID C13698
    KEGG Drug D08275
    ChEBI 34888